UBS has increased its price target for Healthcare Realty Trust (HR) from $18 to $20, while keeping a Neutral rating. This adjustment follows the company's Q3 2026 earnings report and updated guidance, suggesting a slightly more optimistic valuation from the analyst firm.
UBS has updated its price target for Healthcare Realty Trust (HR) to $20 from $18, reflecting a modest upward revision in their valuation. This change comes after HR's third-quarter 2026 earnings report, which included updates on normalized FFO and full-year guidance, indicating that UBS has processed this new information. While the price target increase is positive, the maintained 'Neutral' rating suggests UBS does not see a compelling reason for investors to either buy or sell the stock aggressively. For traders, this is a moderate signal; the short-term impact might be limited as the rating remains unchanged, but it could provide some minor positive sentiment. The key opportunity lies in whether other analysts follow suit or if the company's future performance significantly deviates from current expectations.